Back to mobile site

Moderna (MRNA) downside has played out, HSBC raises rating

November 3, 2023 9:49 AM EDT Send to a Friend
Moderna (NASDAQ: MRNA) was raised to Hold from Reduce at HSBC on Friday, with the firm raising the price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login